The Achondroplasia drugs in development market research report provides comprehensive information on the therapeutics under development for Achondroplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Achondroplasia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Achondroplasia and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Achondroplasia by 13 companies/universities/institutes. The top development phase for Achondroplasia is preclinical with four drugs in that stage. The Achondroplasia pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Achondroplasia pipeline products market are: Tyra Biosciences, Cbiomex and Sanofi.

The key targets in the Achondroplasia pipeline products market include Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC, Atrial Natriuretic Peptide Receptor 2 (Atrial Natriuretic Peptide Receptor Type B or Guanylate Cyclase B or NPR2 or EC, and Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

The key mechanisms of action in the Achondroplasia pipeline product include Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC Inhibitor with six drugs in Phase III. The Achondroplasia pipeline products include four routes of administration with the top ROA being Subcutaneous and seven key molecule types in the Achondroplasia pipeline products market including Small Molecule, and Synthetic Peptide.

Achondroplasia overview

Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body, and kyphosis. Treatment includes growth hormones.

For a complete picture of Achondroplasia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.